Display options
Cite
Ghataore L, Chakraborti I, Aylwin SJ, et al. Effects of mitotane treatment on human steroid metabolism: implications for patient management. Endocr Connect. 2012;1(1):37-47doi: 10.1530/EC-12-0028.
Ghataore, L., Chakraborti, I., Aylwin, S. J., Schulte, K. M., Dworakowska, D., Coskeran, P., & Taylor, N. F. (2012). Effects of mitotane treatment on human steroid metabolism: implications for patient management. Endocrine connections, 1(1), 37-47. https://doi.org/10.1530/EC-12-0028
Ghataore, L, et al. "Effects of mitotane treatment on human steroid metabolism: implications for patient management." Endocrine connections vol. 1,1 (2012): 37-47. doi: https://doi.org/10.1530/EC-12-0028
Ghataore L, Chakraborti I, Aylwin SJ, Schulte KM, Dworakowska D, Coskeran P, Taylor NF. Effects of mitotane treatment on human steroid metabolism: implications for patient management. Endocr Connect. 2012 Jul 21;1(1):37-47. doi: 10.1530/EC-12-0028. Print 2012 Jul 01. PMID: 23781302; PMCID: PMC3682235.
Copy Download .nbib Format: NLM
Share it on

Endocr Connect. 2012 Jul 21;1(1):37-47. doi: 10.1530/EC-12-0028. Print 2012 Jul 01.

Effects of mitotane treatment on human steroid metabolism: implications for patient management.

Endocrine connections

L Ghataore, I Chakraborti, S J Aylwin, K-M Schulte, D Dworakowska, P Coskeran, N F Taylor

Affiliations

  1. Department of Clinical Biochemistry King's College Hospital London, SE5 9RS UK.

PMID: 23781302 PMCID: PMC3682235 DOI: 10.1530/EC-12-0028

Abstract

Mitotane (o,p'-DDD), an oral adrenolytic agent for treatment of advanced adrenocortical carcinoma (ACC), is reported to inhibit cortisol biosynthesis in vitro and enhance production from exogenous cortisol of urinary 6β-hydroxycortisol and unidentified polar unconjugated metabolites. We examined urinary steroid profiles by gas chromatography-mass spectrometry of patients with histologically confirmed ACC following surgery, receiving a) hydrocortisone alone (three males and three females) and b) mitotane and hydrocortisone (six males and 11 females). Samples were collected after plasma mitotane had reached the therapeutic range of 14-20 mg/l. Increased excretion of polar unconjugated steroids during mitotane treatment was confirmed, with 6β-hydroxycortisol and 6β-hydroxy-20-dihydrocortisols predominating. The proportion of additionally hydroxylated metabolites was <2% in untreated controls and 52, 35-52% (mean, range) in the mitotane plus hydrocortisone group. Ratios of 5α-/5β- and 20β-/20α-metabolites of administered cortisol were decreased 50-, 15-fold, and 14-, 8-fold respectively (males, females - mean values) but with no change in metabolite ratios that reflect oxidoreduction at C11 or C20. Patterns of decrease in 5α- relative to 5β-reduced metabolites were similar to those of patients with 5α-reductase 2 deficiency or on treatment with the 5α-reductase 2 inhibitor finasteride but different from those of patients on dutasteride, indicating specific inhibition of 5α-reductase 2. We conclude that mitotane causes consistent changes in cortisol catabolism, most of which have not been previously recognised. These need not interfere with early detection of ACC recurrence. Induction of 6β-hydroxylation offers an explanation for a reported decrease in cortisol bioavailability. Mitotane also has potential as a unique steroid metabolic probe for 20β-reduction.

Keywords: GC–MS; cortisol; mitotane; steroid

References

  1. Clin Endocrinol (Oxf). 2011 Nov;75(5):585-91 - PubMed
  2. Drug Metab Dispos. 1980 May-Jun;8(3):127-30 - PubMed
  3. N Engl J Med. 2007 Jun 7;356(23):2372-80 - PubMed
  4. Endocr Rev. 2011 Feb;32(1):81-151 - PubMed
  5. Clin Endocrinol (Oxf). 1989 Jul;31(1):51-7 - PubMed
  6. J Steroid Biochem. 1973 Nov;4(6):585-91 - PubMed
  7. J Biol Chem. 2009 Jul 24;284(30):19786-90 - PubMed
  8. Gen Comp Endocrinol. 2010 May 1;166(3):489-97 - PubMed
  9. Braz J Med Biol Res. 2000 Oct;33(10):1197-200 - PubMed
  10. Methods Mol Biol. 2006;324:159-75 - PubMed
  11. Endocr Res. 1996 Nov;22(4):751-5 - PubMed
  12. J Clin Endocrinol Metab. 2006 Jun;91(6):2165-70 - PubMed
  13. Eur J Endocrinol. 2011 Apr;164(4):621-6 - PubMed
  14. Cancer Sci. 2008 Jan;99(1):81-6 - PubMed
  15. Ann Endocrinol (Paris). 1981 Jul-Sep;42(3):284-5 - PubMed
  16. J Clin Endocrinol Metab. 1985 Mar;60(3):553-8 - PubMed
  17. Cancer Res. 1979 Jan;39(1):139-45 - PubMed
  18. Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):273-89 - PubMed
  19. Endokrinologie. 1982 Oct;80(2):163-72 - PubMed
  20. Nihon Naibunpi Gakkai Zasshi. 1985 Mar 20;61(3):168-78 - PubMed
  21. Steroids. 2008 Apr;73(4):417-23 - PubMed
  22. Steroids. 2010 Jan;75(1):34-52 - PubMed
  23. J Clin Endocrinol Metab. 1990 Mar;70(3):777-82 - PubMed
  24. Clin Chim Acta. 1978 May 2;85(3):219-29 - PubMed
  25. Steroids. 1966 Jan;7(1):11-29 - PubMed
  26. J Clin Endocrinol Metab. 1971 Feb;32(2):192-200 - PubMed
  27. J Clin Endocrinol Metab. 1964 Dec;24:1303-11 - PubMed
  28. FEBS Lett. 1978 Apr 15;88(2):215-8 - PubMed
  29. J Steroid Biochem. 1978 Dec;9(12):1217-24 - PubMed
  30. Toxicol Appl Pharmacol. 1973 Jan;24(1):101-13 - PubMed

Publication Types